Vivoryon Therapeutics NV (LTS:0R3M) EBIT : €-31.32 Mil (TTM As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV EBIT?

Vivoryon Therapeutics NV's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-13.54 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-31.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vivoryon Therapeutics NV's annualized ROC % for the quarter that ended in Jun. 2024 was -2,334.57%. Vivoryon Therapeutics NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -46,679.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vivoryon Therapeutics NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -84.22%.

Vivoryon Therapeutics NV EBIT Historical Data

The historical data trend for Vivoryon Therapeutics NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV EBIT Chart

Vivoryon Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-7.79

-16.49

-12.20

-28.33

-28.52

Vivoryon Therapeutics NV Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															-12.39	-15.94	-10.74	-17.79	-13.54

Competitive Comparison of Vivoryon Therapeutics NV's EBIT

For the Biotechnology subindustry, Vivoryon Therapeutics NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's EV-to-EBIT falls into.

Vivoryon Therapeutics NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-31.32 Mil.

Vivoryon Therapeutics NV (LTS:0R3M) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vivoryon Therapeutics NV's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-27.618 * ( 1 - 0% )	/	( (1.244	+	1.122)	/ 2 )
=	-27.618	/	1.183
=	-2,334.57 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30.829	-	2.955	-	( 28.583	-	max(0, 3.182	-	29.812	+	28.583	))
=	1.244

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	16.991	-	1.534	-	( 15.346	-	max(0, 1.712	-	16.047	+	15.346	))
=	1.122

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Vivoryon Therapeutics NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-27.074	/	( ( (0.076 + max(-2.059, 0))	+	(0.04 + max(-1.001, 0)) )	/	2 )
=	-27.074	/	( ( 0.076	+	0.04 )	/	2 )
=	-27.074	/	0.058
=	-46,679.31 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.085)	-	(2.955	+	0	+	0.189)
=	-2.059

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.701)	-	(1.534	+	0	+	0.168)
=	-1.001

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vivoryon Therapeutics NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-31.322	/	37.189
	=	-84.22 %

Vivoryon Therapeutics NV EBIT Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (LTS:0R3M) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

VVY:Netherlands 05Y:Germany

Address

Weinbergweg 22, Halle, SN, DEU, 06120

Website

https://www.vivoryon.com

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV Headlines

No Headlines